



GSK at a glance

Ahead Together



Who we are

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.

We aim to positively impact the health of 2.5 billion people by the end of 2030, with ambitious plans for growth and continuing to make GSK a company where everyone can thrive.

What we do

We prioritise innovation in vaccines and specialty medicines to prevent and treat disease.

At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development.

In 2022:

£29.3bn

medicines and vaccine sales

68 vaccines and medicines in development

£5.5bn

R&D investment

10 products exceeding 1bn sales

We focus on four core therapeutic areas: infectious disease, HIV, respiratory/immunology, and oncology.

Our portfolio:

Vaccines



Our unrivalled portfolio targets infectious diseases at every stage of life helping protect people from shingles, meningitis, flu, polio, measles and many more.

Specialty Medicines

We are global leaders in HIV medicines, pioneering new long-acting therapies and HIV prevention. We focus on life-changing cancer medicines and novel treatments for other immune-mediated diseases.

General Medicines

From inhaled medicines for asthma and COPD to antibiotics to medicines for skin diseases, we make life better for millions of people in over 112 countries.



Our priorities

Everyone at GSK is focused on our three long-term priorities:

Innovation

Finding new vaccines and medicines to tackle unmet needs. With better, faster and smarter R&D. Combining the power of genetic and genomic insights into the causes of disease, with the speed and scale of artificial intelligence and machine learning.

Performance

New commitments to growth and a significant step-change in performance. So that more GSK vaccines and medicines than ever before – including innovative new products – reach the people who need them most.

Trust

Delivering our strategy responsibly: always considering the social, environmental and governance impacts of everything we do. We're taking action in six areas where we can make a difference: pricing and access; global health and health security; diversity, equity and inclusion; environmental sustainability; product governance and ethical standards.

In 2022:

18

pipeline assets in phase III/ registration

7

new collaborations and acquisitions

£29.3bn

medicines and vaccine sales

1.85bn

packs of medicines and vaccine doses delivered

1st

in the Access to Medicine Index

2nd

in our industry for the S&P Global Corporate Sustainability Assessment

Our culture

We have over 70,000 people in more than 80 countries worldwide and culture at GSK is something we all own.

We are ambitious for patients

to deliver what matters better and faster.

We are accountable for impact

with clear ownership and support to succeed.

We do the right thing with integrity and care because people count on us.

This powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive.

These are the foundations for how, together, we'll deliver more for our patients, shareholders and GSK people.

Why we do it

We aim to get ahead of disease together – to positively impact the health of 2.5 billion people by the end of 2030.

